2017 Tang Prize Award Lecture
Dr. Emmanuelle Charpentier, a French microbiologist, is well recognized as a world-leading expert in regulatory mechanisms underlying processes of infection and immunity in bacterial pathogens. She is presently Director of the Department of Regulation in Infection Biology, Max Planck Institute for Infection Biology. Her critical role in CRISPR is her original discovery that Cas9’s activity requires trans-activating crRNA (tracrRNA).
She will present The bacterial CRISPR-Cas9 system: a game changer in genome engineering on Sunday, April 23, 2017 at the Chicago's McCormick Place, Room 183AB.
About the Tang Prize
In the advent of industrialization and globalization, humanity has greatly enjoyed the convenience brought about by science and technology, reaping unprecedented benefits made possible by progress and development. Yet, humanity also faces a multitude of critical environmental, socio-cultural, and ethical issues on an unparalleled scale, such as climate change, inequality, and moral degradation. Against this backdrop, Dr. Samuel Yin established the Tang Prize in December 2012 to encourage individuals across the globe to chart the middle path to achieving sustainable development by recognizing and supporting contributors for their revolutionary efforts in the four major fields of Sustainable Development, Biopharmaceutical Science, Sinology, and Rule of Law. The Tang Prize is truly global in reach, with laureates selected on the basis of the originality of their work along with their contributions to society irrespective of their nationality or ethnicity.
Rooted in the long-standing cultural traditions of Chinese philosophical thinking and in an outlook of convergence and mutual enrichment with other traditions, the Tang Prize aims to provide fresh impetus to promote first-class research and development in the 21st century. Ultimately, the Tang Prize seeks to bring about positive change to the global community and to create a brighter future for all humanity.
About the Prize in Biopharmaceutical Science
The Tang Prize in Biopharmaceutical Science recognizes original biopharmaceutical or biomedical research that has led to significant advances towards preventing, diagnosing and/or treating major human diseases to improve human health.
The 2014 Tang Prize in Biopharmaceutical Science was awarded to James P. Allison and Tasuku Honjo for the discoveries of CTLA-4 and PD-1 as immune inhibitory molecules that led to their applications in cancer immunotherapy.
- Dr. Allison presented Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities at EB 2015 on Tuesday, March 31, 2015 at the Boston Convention & exhibition Center, Room 156BC
- Dr. Honjo presented Cancer Immunotherapy by PD-1 Antibody at EB 2016 on Tuesday, April 5, 2016 at the San Diego Convention Center, Room 33ABC.
The 2016 Tang Prize in Biopharmaceutical Science was awarded to Emmanuelle Charpentier (presenting in 2017), Jennifer A. Doudna (presenting in 2018), and Feng Zhang for the development of CRISPR/Cas9 as a breakthrough genome editing platform that promises to revolutionize biomedical research and disease treatment.
For more information on these laureates, please visit the Tang Prize Foundation website